Navigation Links
RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
Date:5/19/2009

TA(R). Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose. Elderly patients appeared to be at increased risk for TD. Prescribing should be consistent with the need to minimize the risk of TD. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including RISPERDAL(R) CONSTA(R). Patients starting treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, RISPERDAL(R) CONSTA(R) elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents.

Orthostatic Hypotension: RISPERDAL(R) CONSTA(R) may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, synco
'/>"/>

SOURCE Janssen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
4. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
5. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
6. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015  The fairness of the proposed ... St. Jude Medical ("St. Jude") is the subject of ... shareholder rights law firm.  The investigation is focusing on ... law by the Board of Directors of THOR for ... July 22, 2015, the Company announced it had reached a ...
(Date:7/27/2015)... 2015 Research and ... of the "Cardiometabolic Drug News Issue" ... pricing is in line with our existing view ... product,s commercial appeal. However, contraindications, side effects, and ... a sizeable share of the fast-acting insulin market. ...
(Date:7/27/2015)... , July 27, 2015  Attorney Advertising-- Bronstein, ... on behalf of purchasers of the securities of ... AMAG -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether AMAG and certain of its officers and/or ...
Breaking Medicine Technology:WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2
... 9 DOR BioPharma, Inc. (DOR or the Company) ... today that it has received Protocol Assistance feedback from ... its confirmatory, pivotal, Phase 3 clinical trial evaluating its ... Graft-versus-Host Disease (GI GVHD). , , The ...
... Potential Benefits of Exenatide to be Prospectively Assessed in Large ... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli ... results from a meta-analysis of cardiovascular (CV) events that showed ... injection use compared to a pooled comparator group treated with ...
Cached Medicine Technology:DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 2DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 3DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 4DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 5DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 6DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 7Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6
(Date:7/28/2015)... ... 28, 2015 , ... Peter Forbes, President of the Veterans Fund of the United States, managing ... the Veterans Coalition, is spearheading a campaign to help homeless Veterans by giving them “A ... and trade skills. Forbes and the UVBH assists and supports Vets through the Veterans ...
(Date:7/27/2015)... ... July 28, 2015 , ... Conducting Advanced ... Techniques to Improve the Quality of Investigations , **Presented by FDAnews and Learning ... and CAPAs have been the #1 reason for 483 observations since 1997! , ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional Women (NAPW) ... Woman of the Year Circle. She is recognized with this prestigious distinction for leadership ... is the nation’s leading networking organization exclusively for professional women. , “I’m pleased to ...
(Date:7/27/2015)... MA (PRWEB) , ... July 27, 2015 , ... ... has transformed the science of the little-known and incurable disease, facioscapulohumeral muscular dystrophy ... the American Academy of Neurology (AAN). The FSHD care guideline is published today. ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
Breaking Medicine News(10 mins):Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 2Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2
... , ... Reportlinker.com announces that a new market research report is ... , http://www.reportlinker.com/p0171106/Diet-Foods--2010-Edition.html , The diet foods market ... sectors. These have followed different growth paths. The old established ...
... American College of Physicians (ACP) has issued a ... physicians, and caregivers. The Journal of ... Patients and Physicians: Ethical Guidance to Optimize Relationships." ... to help physicians manage relationships with patients and ...
... fast-acting compound that appears to improve cognitive function impairments ... progressive Alzheimer,s disease has been identified by scientists at ... University Medical Center Program in Drug Discovery. Researchers hope ... The compound benzylquinolone carboxylic acid (BQCA) has ...
... , MOUNTAIN ... Inc. (Nasdaq: OMCL ), a leading provider of ... NewYork-Presbyterian Hospital has chosen Omnicell as its primary vendor ... safety of medications for our patients, we need a system that ...
... significantly, study finds , TUESDAY, Jan. 12 (HealthDay News) -- ... heart rate boosts the risk of dying from a heart ... Norwegian researchers tracked the health of about 50,000 healthy adults, ... During that time, 6,033 men and 4,442 women died. Heart ...
... ... announcing a new meal plan catering to vegetarian dieters. , ... (PRWEB) January 12, 2010 -- Diet-to-Go, a ... line of meals that can help millions of health-conscious Americans eat great, lose weight, ...
Cached Medicine News:Health News:Reportlinker Adds Diet Foods- 2010 Edition 2Health News:Reportlinker Adds Diet Foods- 2010 Edition 3Health News:Reportlinker Adds Diet Foods- 2010 Edition 4Health News:Reportlinker Adds Diet Foods- 2010 Edition 5Health News:Reportlinker Adds Diet Foods- 2010 Edition 6Health News:Reportlinker Adds Diet Foods- 2010 Edition 7Health News:Reportlinker Adds Diet Foods- 2010 Edition 8Health News:Reportlinker Adds Diet Foods- 2010 Edition 9Health News:Reportlinker Adds Diet Foods- 2010 Edition 10Health News:Reportlinker Adds Diet Foods- 2010 Edition 11Health News:Reportlinker Adds Diet Foods- 2010 Edition 12Health News:Reportlinker Adds Diet Foods- 2010 Edition 13Health News:Reportlinker Adds Diet Foods- 2010 Edition 14Health News:New ethical guidance from ACP for patient-physician-caregiver relationship 2Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 2Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 3Health News:NewYork-Presbyterian Hospital Selects Omnicell for Medication Management 2Health News:NewYork-Presbyterian Hospital Selects Omnicell for Medication Management 3Health News:NewYork-Presbyterian Hospital Selects Omnicell for Medication Management 4Health News:Faster Heart Rate May Raise Risk of Heart Attack Death 2Health News:Diet-to-Go Delivers Deliciously Healthy Vegetarian Meals 2
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... has additional hardware and software features to ... demanding clinics or teaching institutions. Standard with ... parameters for experimental or clinical studies. Ethernet ... for further tests including Flicker- and Color ...
... Designed around the patented ... Octopus 301 sets the trend ... decade. Ideal for routine screening ... performance, accuracy and quality ...
... FDT is a breakthrough in visual field testing ... in pre-test. Introducing FDT, the first visual field ... enough to be used even in pre-test. Affordably ... trials behind it to validate performance. The instrument ...
Medicine Products: